PATIENTS with autoimmune conditions across rheumatology, dermatology, gastroenterology and ophthalmology with be able to access AbbVie's Humira (adalimumab) citrate-free formulation through the Pharmacecutical Benefits Scheme (PBS) from 01 Apr.
A survey of patients with inflammatory bowel disease found the new formulation was associated with a reduction in pre-administration anxiety and a decrease in injection site pain.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Mar 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Mar 21
